Structure Therapeutics Inc. Sponsored ADR $GPCR Holdings Boosted by Quinn Opportunity Partners LLC

Quinn Opportunity Partners LLC raised its stake in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 90.9% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 42,000 shares of the company’s stock after acquiring an additional 20,000 shares during the period. Quinn Opportunity Partners LLC owned 0.07% of Structure Therapeutics worth $871,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in GPCR. National Bank of Canada FI boosted its position in Structure Therapeutics by 1,448.2% during the 1st quarter. National Bank of Canada FI now owns 2,957 shares of the company’s stock valued at $51,000 after purchasing an additional 2,766 shares during the period. Assetmark Inc. lifted its stake in Structure Therapeutics by 39.9% in the second quarter. Assetmark Inc. now owns 2,877 shares of the company’s stock valued at $60,000 after buying an additional 820 shares during the last quarter. ANTIPODES PARTNERS Ltd boosted its holdings in shares of Structure Therapeutics by 310.7% during the first quarter. ANTIPODES PARTNERS Ltd now owns 4,247 shares of the company’s stock valued at $74,000 after acquiring an additional 3,213 shares during the period. Signaturefd LLC grew its position in shares of Structure Therapeutics by 6,550.0% during the second quarter. Signaturefd LLC now owns 6,650 shares of the company’s stock worth $138,000 after acquiring an additional 6,550 shares during the last quarter. Finally, Parallel Advisors LLC acquired a new stake in shares of Structure Therapeutics in the 2nd quarter worth about $171,000. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Structure Therapeutics Price Performance

NASDAQ GPCR opened at $35.92 on Thursday. Structure Therapeutics Inc. Sponsored ADR has a 12 month low of $13.22 and a 12 month high of $38.48. The company has a market capitalization of $2.07 billion, a P/E ratio of -29.44 and a beta of -1.63. The company’s 50 day simple moving average is $27.24 and its 200 day simple moving average is $23.20.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.01). On average, analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -0.82 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have issued reports on GPCR shares. Lifesci Capital raised shares of Structure Therapeutics to a “strong-buy” rating in a research note on Monday, September 8th. Piper Sandler reiterated an “overweight” rating on shares of Structure Therapeutics in a research report on Tuesday, October 28th. HC Wainwright lowered their target price on Structure Therapeutics from $75.00 to $60.00 and set a “buy” rating on the stock in a research report on Thursday, August 7th. Guggenheim cut their target price on Structure Therapeutics from $92.00 to $90.00 and set a “buy” rating on the stock in a research note on Thursday, August 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat, Structure Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $68.67.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.